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Down-regulation of PLC2–-catenin
pathway promotes activation and expansion
of myeloid-derived suppressor cells in cancer
Aude-Hélène Capietto,1 Seokho Kim,1 Dominic E. Sanford,2
David C. Linehan,2 Masaki Hikida,4 Tomohiro Kumosaki,4
Deborah V. Novack,3 and Roberta Faccio1
of Orthopedics, 2Department of Surgery, 3Department of Medicine, Washington University School of Medicine,
St. Louis, MO
4Laboratory for Lymphocyte Differentiation, RIKEN Research Center for Allergy and Immunology, Tsurumi, Yokohama,
Kanagawa 230-0045, Japan

CORRESPONDENCE
Roberta Faccio:
faccior@wustl.edu
Abbreviation used: Bax, Bcl-2associated X protein; -cat.cKO,
-catenin conditional knockout; -cat.CA, -catenin constitutively active; Bcl-2,
B-cell lymphoma-2; Bcl-xl,
B-cell lymphoma-extra large;
BLI, bioluminescence imaging;
C/EBP-, CAAT/enhancer
binding protein-; DAG, diacyl
glycerol; DCFDA, cellular ROS
detection assay; GSK3, glycogen synthase kinase-3; HPC,
hematopoietic progenitor cells;
HSC, hematopoietic stem cells;
IP3, inositol triphosphate;
IRF-8, IFN-regulatory factor 8;
ITAM, immunoreceptor tyrosine-based activation motif;
ITIM, immunoreceptor tyrosine-based inhibition motif;
LLC, Lewis lung carcinoma;
LysM, lysozyme M; MDSC,
myeloid-derived suppressor cell;
M-CSF, macrophage colonystimulating factor; NO, nitric
oxide; PDBu, phorbol 12,13dibutyrate; PIP2, phosphatidylinositol 4,5-bisphosphate; PIR-B,
immunoglobulin-like receptor-B;
PKC, protein kinase C; PLC2,
phospholipase C--2; ROS,
reactive oxygen species.

Myeloid-derived suppressor cells (MDSCs) favor tumor promotion, mainly by suppressing
antitumor T cell responses in many cancers. Although the mechanism of T cell inhibition is
established, the pathways leading to MDSC accumulation in bone marrow and secondary
lymphoid organs of tumor-bearing hosts remain unclear. We demonstrate that downregulation of PLC2 signaling in MDSCs is responsible for their aberrant expansion during
tumor progression. PLC2/ MDSCs show stronger immune-suppressive activity against
CD8+ T cells than WT MDSCs and potently promote tumor growth when adoptively transferred into WT mice. Mechanistically, PLC2/ MDSCs display reduced -catenin levels,
and restoration of -catenin expression decreases their expansion and tumor growth.
Consistent with a negative role for -catenin in MDSCs, its deletion in the myeloid population leads to MDSC accumulation and supports tumor progression, whereas expression of
-catenin constitutively active reduces MDSC numbers and protects from tumor growth.
Further emphasizing the clinical relevance of these findings, MDSCs isolated from pancreatic cancer patients show reduced p-PLC2 and -catenin levels compared with healthy
controls, similar to tumor-bearing mice. Thus, for the first time, we demonstrate that
down-regulation of PLC2–-catenin pathway occurs in mice and humans and leads to
MDSC-mediated tumor expansion, raising concerns about the efficacy of systemic
-catenin blockade as anti-cancer therapy.

Accumulating evidence indicates that myeloidderived suppressor cells (MDSCs) are critically
involved in tumor progression. Despite the
ambiguity surrounding their origin, MDSCs
are recognized for their ability to suppress antitumor immune responses. MDSCs exert their
pro-neoplastic effects through the release of
small soluble oxidizers, impairment of T cell/
antigen recognition, and depletion of essential
amino acids from the local extracellular environ
ment, all ultimately leading to T cell suppression (Mazzoni et al., 2002; Kusmartsev and
Gabrilovich, 2003; Liu et al., 2003; Kusmartsev
et al., 2004;). Additionally, MDSCs shift immune
regulation to a state favoring both tumor escape
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and proliferation through overproduction of
cytokines and angiogenic factors (Kusmartsev
and Gabrilovich, 2006). Thus, it is not surprising that presence of MDSCs in the blood
and tumor biopsies of cancer patients is associated with poor prognosis (Almand et al.,
2001; Lechner et al., 2011; Solito et al., 2011;
Porembka et al., 2012).
MDSCs comprise a heterogeneous population of immature myeloid cells (Bronte
et al., 2000; Gabrilovich et al., 2001; Liu et al.,
2003; Kusmartsev et al., 2004; Kusmartsev et al.,
2005; Zea et al., 2005; Gallina et al., 2006),
identified by the co-expression of Gr-1 and m
© 2013 Capietto et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months
after the publication date (see http://www.rupress.org/terms). After six months
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MDSC expansion in the bone marrow of tumor-bearing
mice and enhances MDSC immunosuppressive activities via
modulation of -catenin levels. Together these results highlight a novel molecular pathway regulating the expansion of
MDSCs and their crucial role in tumor progression.
RESULTS
MDSCs are responsible for increased
tumor growth in PLC2/ mice
To understand the mechanism responsible for the impaired
antitumor T cell response observed in PLC2/ mice, we
measured the percentage of MDSCs after s.c. inoculation
of B16 melanoma and Lewis lung carcinoma (LLC) cell
lines. Consistent with a significant increase in s.c. tumor
growth in PLC2/ mice, we also found a higher percentage
of Gr-1+CD11b+ MDSCs in the bone marrow, spleen, and
tumor site 14 d after inoculation of both tumor cell lines (Fig. 1,
A and B). The increase in percentage of MDSCs observed
in the null mice was not detected at baseline, reflecting a rather
specific response to the tumor itself (not shown). Between the
two cell lines, LLC induced stronger MDSC accumulation
than B16 cells in both PLC2/ and WT mice, and thus this
cell line was used for all subsequent experiments. Next,
to determine whether the expanded MDSC population observed in the null mice was a consequence of greater tumor
growth, we injected WT and PLC2/ mice with 105 LLC
and sacrificed the animals 7 d after tumor challenge when no
detectable differences in tumor weight were yet observed
(Fig. 1 C). PLC2/ mice already displayed greater MDSC
accumulation in bone marrow and spleen, whereas only a
small percentage of MDSCs was detected in the tumor at this
time in both genotypes (Fig. 1 C).
To determine whether increased numbers of MDSCs
are responsible for enhanced tumor growth in PLC2/
mice, we adoptively transferred 3 × 106 MDSCs isolated from
LLC tumor-bearing PLC2/ or WT mice into WT animals.
MDSCs were i.v. injected into the recipient mice 3 and 6 d
after s.c. LLC inoculation. Tumor growth was monitored for
2 wk, and the percentage of MDSCs in the spleen was measured at time of sacrifice. We found that adoptive transfer of
PLC2/ MDSCs into WT recipients significantly enhanced
tumor growth compared with animals receiving WT MDSCs,
and it also further increased MDSC accumulation in the
spleen (Fig. 2 A). To address whether the expansion of MDSCs
caused by administration of PLC2-deficient MDSCs was
caused by proliferation of the null cells or by increased expansion of endogenous MDSCs, we adoptively transferred
CD45.2+ PLC2/ or WT MDSCs into tumor-bearing
CD45.1+ WT recipients. Mice injected with saline were used
as controls. Tumor growth was monitored for 14 d and the
percentage of endogenous CD45.1+ MDSCs and total
Gr-1+CD11b+ MDSCs (CD45.1+ and CD45.2+) in the spleen
was analyzed at time of sacrifice. As in Fig. 2 A, animals receiving PLC2/ MDSCs showed increased tumor growth
compared with animals receiving WT MDSCs, accompanied by greater MDSC expansion (Fig. 2 B). Interestingly, the
PLC2/-catenin pathway regulates MDSCs in cancer | Capietto et al.
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integrin (CD11b) in mice. More recently, MDSCs were subdivided into two different subsets based on the expression of
Ly6C and Ly6G. One subset comprises monocytic and mononuclear CD11b+Ly6GLy6Chigh cells, called MO-MDSCs,
which primarily release NO to suppress T cell activation
(Movahedi et al., 2008;Youn et al., 2008). The second subset,
termed PMN-MDSCs, includes CD11b+Ly6G+Ly6Clow cells
with granulocytic and polymorphonuclear morphology and
they exert T cell inhibition by producing mainly reactive
oxygen species (ROS). The expansion of these two MDSC
subsets has been shown to be tumor cell line dependent. Most
tumors show increased PMN-MDSCs, whereas MO-MDSCs
are expanded in only a few models (Youn et al., 2008). Nevertheless, both PMN- and MO-MDSC subsets exert comparable immune suppressive activity primarily against CD8+ T cells.
A large body of work has focused on the identification
of the factors modulating MDSC activation and the signals
mediating their recruitment to the tumor microenvironment
or secondary lymphoid organs. Several tumor-derived growth
factors, including macrophage colony-stimulating factor
(M-CSF), IL-6, and granulocyte/macrophage colony-stimulating
factor (GM-CSF) promote the expansion of MDSCs through
stimulation of myelopoiesis and inhibition of the differentiation of mature myeloid cells reviewed by (Gabrilovich and
Nagaraj, 2009). Other factors such as IFN-, ligands for TLRs,
and TGF produced mainly by activated T cells and tumor
stroma, are involved in MDSC activation. In most instances,
phosphorylation of signal transducer and activator of transcription 3 (STAT3) and STAT1 are observed in MDSCs
during tumor progression. Although STAT3 was shown to
modulate MDSC differentiation and function, recent reports
suggest that STAT3 primarily controls the ability of MDSCs
to suppress antigen-dependent T cell activation (Kortylewski
et al., 2005; Chalmin et al., 2010). Other transcription factors
important for myeloid cell fate determination, such as PU.1
(Spi-1) or CAAT/enhancer binding protein- (C/EBP-),
have been implicated in MDSC differentiation and immunesuppressive functions (Schroeder et al., 2003; Marigo et al.,
2010). However, one of the major unresolved questions is the
mechanism leading to MDSC expansion in the bone marrow,
an event that occurs very early during tumor progression,
even when the tumor itself is at a distant site. Thus, the focus
of our work is to better understand the mechanisms involved
in MDSC accumulation in response to the tumor.
Activation of PLC2, an enzyme converting phosphatidylinositol 4,5-bisphosphate (PIP2) into diacylglycerol (DAG)
and inositol triphosphate (IP3), is implicated in proliferation
and migration of several cancers (Smith et al., 1998; Feng
et al., 2012). However, its deletion in the host also leads to
increased tumor growth (Zhang et al., 2011). We have recently
shown that PLC2/ mice are more susceptible to tumor
growth in bone despite a decrease in osteoclast number and
function. Although PLC2 is not required for T cell activation,
we observed impaired CD8+ T cell responses in PLC2/
tumor-bearing mice (Zhang et al., 2011). Our current study
shows that down-regulation of PLC2 signaling promotes
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accumulation of MDSCs after adoptive transfer of either WT
or PLC2/ cells was due to expansion of endogenous
CD45.1+ MDSCs, as their percentage was similar to that of
total MDSCs (Fig. 2 B and not depicted). This finding indicates that the transfer of exogenous PLC2-deficient MDSCs
into WT recipient animals causes the expansion of endogenous
MDSCs, which might be the result of enhanced tumor growth.
Next, to use a second approach to show that PLC2 de
ficiency in the myeloid population, including MDSCs, is
responsible for the observed tumor phenotype, we turned to
PLC2 conditional KO mice (PLC2cKO), in which deletion
of PLC2 is under control of LysM-Cre. Reduced PLC2
expression in MDSCs was confirmed by Western blot, and
similarly to the global PLC2/ mice, PLC2cKO animals
also displayed increased tumor growth and MDSC accumulation compared with LysM-Cre controls (not shown).
As MDSCs have also a recognized role in tolerance, we
next analyzed whether PLC2/ mice, which are on a
C57BL/6 background, could allow growth of the allogeneic
4T1 breast cancer cell line derived from BALB/c mice. 5 × 106
4T1 tumor cells were inoculated s.c. in WT and PLC2/
mice and tumor growth followed for 2 wk. As expected by
the different background of the recipient C57BL/6 mice and
the 4T1 tumor cell line isolated from BALB/c mice, the
tumor engraftment was rejected in WT mice (Fig. 3). However, 4T1 tumor cells grew in PLC2/ mice with a concomitant accumulation of MDSCs in the bone marrow and a
JEM Vol. 210, No. 11

2.5 fold-increase in the percentage of MDSCs in the spleen
(Fig. 3). All together these results indicate that PLC2 is a
negative regulator of MDSC expansion and function in
tumor-bearing hosts.
PLC2 deficiency favors MDSC accumulation
over myeloid cell differentiation in vitro
To better understand the role of PLC2 in MDSC accumulation, we isolated MDSCs from the spleen of tumor-bearing
mice and analyzed the balance between anti- (Blc-2, Bcl-xl)
and proapoptotic (Bax) signals by quantitative RT-PCR.
PLC2/ MDSCs showed similar relative mRNA expression levels of Bcl-2, Bcl-xl, and Bax to WT MDSCs (not
depicted). Next, we wondered whether PLC2 deficiency
would affect the cell fate differentiation from myeloid progenitor cells in the bone marrow. We isolated lineage negative
hematopoietic progenitor cells from PLC2/ or WT bone
marrow and cultured them in the presence of GM-CSF, IL-4,
and tumor conditioned medium (TCM) (Bronte et al., 2000;
Youn et al., 2008). After 5 d, we determined the percentage
of cells expressing DCs (CD11c), mature DCs (B7.2), macrophages (F4/80), and granulocyte lineage (Gr-1) markers. We
found a significant reduction in the percentage of F4/80positive cells (PLC2/: 31.6 ± 1.3% versus WT: 53.3 ±
1.4%; P = 0.00004), as well as CD11c (PLC2/: 22.3 ± 2.3%
versus WT: 35.7 ± 3.0%; P = 0.004) and CD11c/B7.2-positive
cells (PLC2/: 13.8 ± 1.7% versus WT: 24.5 ± 2.2%;
2259
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Figure 1. PLC2 deficiency induces
greater tumor growth and MDSC accumulation. (A and B) 105 B16 melanoma (A) or
LLC (B) cells were s.c. injected into PLC2/
or WT mice and tumor growth was evaluated
for 14 d. Percentage of MDSCs in the bone
marrow, spleen, and tumor site was analyzed
by FACS using anti–Gr-1 and CD11b staining.
Results represent mean ± SD (B16: n = 5,
experiment done in duplicate; LLC: n = 3,
experiment repeated 4 times). *, P < 0.05;
**, P < 0.01; ***, P < 0.001. (C) 105 LLC cells were
s.c. injected in PLC2/ or WT mice. 7 d after
tumor challenge, the tumor was resected and
weighed. Percentage of MDSCs from bone
marrow, spleen and tumor were then analyzed by FACS staining (Gr-1+CD11b+, MDSCs).
Results represent mean ± SD (n = 4). Data are
reported from one of two similar independent
experiments. **, P < 0.01.
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P = 0.003) in the cultures from PLC2-deficient cells compared with WT. In contrast, the percentage of Gr-1+ cells was
significantly increased in PLC2/ cultures compared with
WT (PLC2/: 37.1 ± 0.9% versus WT: 12.0 ± 1.6%; P =
0.0001). This result suggests that PLC2 deficiency favors
MDSC accumulation over myeloid cell differentiation.

Figure 2. Adoptive transfer of PLC2/ MDSCs enhances tumor
growth in WT mice. (A) WT mice s.c. inoculated with LLC cells were
adoptively transferred on days 3 and 6 with 3 × 106 WT or PLC2/
MDSCs from LLC tumor–bearing mice. Tumor growth was followed for
14 d, and the percentage of Gr-1+CD11b+ MDSCs isolated from spleens
was determined by FACS. Mean ± SD (n = 5) are shown. Data are re
ported from one of two similar experiments. **, P < 0.01; ***, P < 0.001.
(B) 3 × 106 WT or PLC2/ MDSCs were isolated from the spleen of
tumor-bearing CD45.2+ mice and inoculated i.v. into CD45.1+ WT mice on
days 3 and 6 after LLC tumor challenge. The tumor growth in CD45.1+ WT
recipients was monitored for 14 d, and the percentage of endogenous
CD45.1+ Gr-1+CD11b+ MDSCs in spleen was determined by FACS. Mean ±
SD (n = 5) are shown. Data are reported from one of two similar independent experiments. *, P < 0.05; **, P < 0.01.
2260

Figure 3. PLC2/ mice permit 4T1 allogeneic tumor growth.
5 × 106 4T1 mammary tumor cells were s.c. injected in PLC2/ or WT
mice and tumor growth was evaluated for 14 d. Percentage of MDSCs in
spleen was then analyzed by FACS using anti–Gr-1 and CD11b staining.
Results represent mean ± SD (n = 3). One representative experiment of
two is shown. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
PLC2/-catenin pathway regulates MDSCs in cancer | Capietto et al.
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PLC2 deficiency expands PMN- and MO-MDSC subsets
and potentiates their immunosuppressive functions
To gain more insights into the role of PLC2 in MDSCinduced tumor progression, we performed phenotypic and
functional analyses comparing WT and PLC2/ MDSCs
during tumor progression. We measured the relative proportion
of PMN-MDSCs (CD11b+Ly6G+Ly6Clow) and MO-MDSCs
(CD11b+Ly6GLy6Chigh) by FACS in PLC2/ and WT
mice. We first confirmed that the percentage of both PMNand MO-MDSC subsets in bone marrow and spleen was

similar at baseline in the two genetic backgrounds (Fig. 4 A).
PMN-MDSCs represented the dominant subpopulation
before and after the tumor challenge in both WT and KO (Fig. 4,
A and B). However, both MDSC subfractions were significantly increased in bone marrow and spleen of PLC2/
mice compared with WT mice in response to LLC-tumor
inoculation (Fig. 4 B). Thus, PLC2 does not seem to exert
differential effects on PMN- and MO-MDSC subsets.
Next, to determine whether PLC2/ MDSCs exhibited stronger immunosuppressive functions compared with
WT, in addition to being more numerous, we examined the
inhibitory effects of PMN- and MO-MDSCs on T cell proliferation in vitro. As MDSCs were shown to suppress both
antigen-driven and mitogen-driven T cell proliferation, we
examined the immune-suppressive activity of MDSCs under
both conditions. Splenocytes from OT-1 transgenic mice
were labeled with CFSE and incubated with MHC class I–
restricted SIINFEKL (OT-1) peptide (10 pM) to induce
CD8+ T cell antigen–specific proliferation or with anti-CD3
antibody (10 µg/ml) for mitogen-driven CD8+ T cell stimulation.The immune-suppressive effects of MDSCs were determined by culturing WT and PLC2/ PMN- or MO-MDSCs
with three different ratios of splenocytes (1:10; 1:5; 1:1). Proliferation of targeted CD8+ T cells was measured in terms of
CFSE dilution by flow cytometric analysis 72 h later. We
found that both PLC2/ PMN- and MO-MDSCs had
greater immune-suppressive effects on CD8+ T cell proliferation than WT MDSCs in both antigen- and mitogen-driven
T cell stimulatory conditions (Fig. 5, A and B). It is established
that PMN-MDSCs inhibit CD8+ T cell proliferation mainly
through ROS production and that MO-MDSCs induce
T cell apoptosis mostly via NO release.To evaluate the mechanism by which PLC2 deficiency controls MDSC immune
suppressive activity, we measured ROS and NO levels in
PMN- and MO-MDSCs in response to PMA (300 nM) or
LPS (1 µg/ml) for indicated time. As expected (Movahedi
et al., 2008; Youn et al., 2008), WT PMN-MDSCs predominantly produced ROS, whereas WT MO-MDSCs mainly released nitrites (Fig. 5, C and D). In contrast, PMN-MDSCs

Published October 14, 2013

Ar ticle

and MO-MDSCs from PLC2/ mice released both high
levels of ROS and NO (Fig. 5, C and D). Thus, PLC2 deficiency in both MDSC subsets induces higher release of soluble oxidizers, making them more effective in suppressing both
Ag-specific and nonspecific immune responses.

Figure 4. PLC2 deficiency leads to increased PMN- and MOMDSCs in tumor-bearing mice. (A and B) Bone marrow and spleens
from tumor-free (A, No Tumor) or LLC tumor–bearing (B, Tumor) WT and
PLC2/ mice were harvested, and single-cell suspensions were stained
for Ly6G and Ly6C markers. Percentages of WT and PLC2/ PMN-MDSCs (CD11b+Ly6G+Ly6Clow) and MO-MDSCs (CD11b+Ly6G-Ly6Chigh) are
shown. Data are expressed as mean ± SD (n = 7). Cumulative results from
two experiments are shown (A and B). *, P < 0.05; **, P < 0.01.
JEM Vol. 210, No. 11

-catenin deficiency in myeloid cells leads to greater
tumor growth and MDSC accumulation
To further understand the importance of -catenin downregulation in MDSCs in vivo, we turned to the Cre-loxP
recombination system to conditionally delete -catenin in
myeloid cells. -catenin–floxed mice were bred with animals
expressing the Cre recombinase under the control of Lysozyme M (LysM-Cre/-cateninflox/flox; herein defined as -cat.
cKO), and deletion of -catenin in MDSCs was confirmed
by Western blot (not shown). We used animals expressing
either the Cre recombinase (LysM-Cre/-cateninwt/wt) or the
floxed allele (-cateninflox/flox) as a control (CTR). As no differences in tumor growth and MDSC expansion in the two
control genotypes were observed, we used either one or the
other as control group. LLC tumor cell line was inoculated
s.c. into -cat.cKO or control mice, and tumor growth was
followed by caliper measurements for 14 d.The percentage of
MDSCs in the bone marrow, spleen, and tumor site was analyzed by flow cytometry at time of sacrifice. Similarly to
PLC2/ mice, -cat.cKO animals displayed greater tumor
growth and over twofold increase in the percentage of MDSCs
in spleen and tumor site compared with CTR (Fig. 6 C).
A significant increase in the percentage of MDSCs in the
bone marrow was also observed.To further determine the ability of -catenin-deficient MDSCs to support tumor growth,
we adoptively transferred MDSCs isolated from tumor-bearing
-cat.cKO or CTR mice into tumor-bearing WT mice. Mice
receiving saline were used as additional controls. We found
that mice transferred with -cat.cKO MDSCs displayed
enhanced tumor volume and twofold increase in splenic
MDSCs compared with animals receiving CTR MDSCs or
saline (Fig. 6 D).
-catenin stabilization in myeloid cells protects from tumor
growth by reducing MDSC accumulation and function
To further demonstrate that -catenin is a critical modulator of
MDSC expansion in response to tumor, we turned to a similar
LysM-Cre-loxP genetic mouse model to express a constitutively
active mutant of -catenin (LysM-Cre/-cateninfloxEx3/floxEx3;
herein defined as -cat.CA; Harada et al., 1999) in myeloid cells,
including MDSCs (not shown). LLC cells were inoculated s.c.
into -cat.CA and LysM-Cre CTR mice. Tumor growth was
monitored every 2 d, and MDSC accumulation in bone marrow,
spleen, and tumor site was evaluated 14 d after tumor challenge.
In contrast to -cat.cKO mice, expression of a stable form of
-catenin in MDSCs reduced tumor growth compared with
2261
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Reduced -catenin levels are observed in PLC2/ MDSCs
Dysregulated -catenin signaling has been noted in many
cancers. Furthermore, -catenin pathway is also known to
modulate the self-renewal and maintenance of hematopoietic
stem cells and myeloid progenitor cells (Scheller et al., 2006).
Because MDSCs are immature myeloid progenitor cells, we
hypothesized that -catenin could be an important player in
their development. First, we confirmed deletion of PLC2
and reduced phosphorylation levels of the PLC2 effector
PKC (p-PKC; Fig. 6 A). Next, we measured -catenin and
phosphorylated-GSK3 (p-GSK3) levels inWT and PLC2/
MDSCs isolated from tumor-bearing mice by Western blot.
Surprisingly, we observed a striking decrease in -catenin and
p-GSK3 levels in PLC2/ MDSCs compared with WT
(Fig. 6 A). Because PKC has been previously shown to stabilize -catenin protein levels in T cells (Lovatt and Bijlmakers,
2010), we wondered if reduced PKC activation in PLC2/
MDSCs could be responsible for decreasing -catenin levels.
To address this question, we turned to the DAG-analogue
phorbol 12,13-dibutyrate (PDBu), which can induce PKC

activation similarly to endogenous DAG but even in the absence of PLC2 (Castagna et al., 1982). Whole PLC2/
bone marrow cells were cultured in the presence of PDBu
for 18 h, MDSCs were isolated and -catenin protein levels
were determined by Western blot. Results show increased
-catenin protein levels in PLC2-deficient MDSCs treated
with PDBu compared with untreated cells (Fig. 6 B), indicating that PLC2 can regulate -catenin levels via DAGdependent PKC activation.
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CTR mice (Fig. 7 A). Although the percentage of MDSCs was
not different in the bone marrow, a significant decrease in MDSC
accumulation was observed in the spleen and tumor site of
-cat.CA mice (Fig. 7 A).To determine whether stabilization of
-catenin levels in MDSCs would affect their immune suppressive activity in addition to their expansion, we isolated MDSCs
from the spleen of tumor-bearing CTR and -cat.CA mice and
co-cultured these cells with WT CFSE-labeled splenocytes at
1:5 and 1:1 ratios. CD8+ T cell proliferation was induced by
incubation with anti-CD3 antibody for 72 h and analyzed by
FACS.Whereas the T cell proliferation rate was similar in CTRand -cat.CA-MDSC cultures at 1:5 ratio, we found that WT
2262

MDSCs were more potent inhibitors than -cat.CA MDSCs at
1:1 ratio (Fig. 7 B). Collectively, these results indicate that modulation of -catenin levels in MDSCs is critical for their accumulation and function and for modulation of tumor progression.
-catenin stabilization in PLC2/ MDSCs decreases
their accumulation and immune suppressive activity
Next, to determine if PLC2 controls MDSC expansion
in response to tumor via -catenin, we bred LysM-Cre
PLC2 conditional KO mice (PLC2cKO) with LysM-Cre/
-cateninfloxEx3/floxEx3 mice (-cat.CA) to obtain the doublemutant PLC2cKO/-cat.CA animals. Because the double
PLC2/-catenin pathway regulates MDSCs in cancer | Capietto et al.
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Figure 5. PLC2/ MDSCs are more potent
immune suppressors than WT MDSCs in vitro.
(A and B) T cell proliferation assay. PMN- or MOMDSCs isolated from WT and PLC2/ mice
were co-cultured for 3 d with CFSE-labeled splenocytes from OT-1 transgenic mice (1:10, 1:5, and
1:1 ratios) and stimulated with SIINFEKL peptide
(10 pM) in antigen-driven (A) or with anti-CD3
(10 µg/ml) in mitogen-driven (B) experiments. Bar
graphs show mean ± SD of three independent
experiments. *, P < 0.05; **, P < 0.01. Representative flow cytometric analysis of CD8+ T cell proliferation (shown as CFSE dilution) in the presence
of WT (dashed line) and PLC2/ (solid line)
MDSCs is also shown. (C and D) Suppressive
mechanisms of PMN- and MO-MDSCs isolated
from WT and PLC2/ mice. Level of ROS (mean
fluorescence intensity, MFI) in PMN and MO subsets in response to PMA stimulation (300 nM for
30 min) was measured using DCFDA staining and
FACS. NO2 release in supernatant of 105 MDSCs
subfractions was assayed by a standard Greiss
reaction after LPS stimulation (1 µg/ml for 24 h; D).
Mean ± SD from three independent experiments
are shown. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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mutant mice were born at less than Mendelian rates, rendering
the analysis of their tumor phenotype very difficult, we generated radiation chimeras consisting of lethally irradiated WT
recipient mice transplanted with bone marrow cells from doublemutant PLC2cKO/-cat.CA animals, PLC2cKO or LysMCre control mice. 4 wk after bone marrow transplantation,
LLC cells were s.c. inoculated into the transplanted mice.
Tumor growth was followed for 14 d and the percentage of
MDSCs was evaluated by flow cytometry at time of sacrifice.
Expression levels of PLC2 and -catenin in MDSCs in all
chimeric mice were determined by Western blot (Fig. 7 C).
Similar to the global PLC2/ mice, PLC2cKO chimeric
mice also displayed increased tumor growth and MDSC accumulation compared with LysM-Cre chimeric controls (CTR;
Fig. 7 C). In contrast, chimeric mice bearing double-mutant
PLC2cKO/-cat.CA bone marrow cells showed significantly
lower tumor growth and MDSC expansion than chimeric
mice transplanted with PLC2cKO cells (Fig. 7 C). To finally
determine whether reduced percentage of PLC2cKO/-cat.
CA MDSCs was a consequence of decreased tumor growth,
we injected CTR, PLC2cKO, and PLC2cKO/-cat.CA
JEM Vol. 210, No. 11

mice with 105 LLC and sacrificed the animals 5 d after tumor
challenge when no detectable differences in tumor weight
were yet observed (Fig. 7 D). Similar to the global PLC2deficient mice, we observed greater accumulation of PLC2cKO
MDSCs compared with CTR in mice with similar tumor size
(Fig. 7 D). In contrast, PLC2cKO/-cat.CA mice showed
significantly lower MDSC expansion than PLC2cKO mice
(Fig. 7 D). Consistent with this observation, the percentage of
CD8+ T cells infiltrating the tumor was significantly increased in PLC2cKO/-cat.CA compared with PLC2cKO
(Fig. 7 E). As these findings suggested that stabilization of
-catenin levels in PLC2cKO MDSCs impairs cell immune
suppressive activity, we performed functional T cell proliferation assays. CTR-, PLC2cKO-, and PLC2cKO/-cat.CAMDSCs were cultured with CFSE-labeled WT splenocytes
stimulated with anti-CD3 antibody (10 µg/ml). After 3 d, the
proliferation of targeted CD8+ T cells was analyzed in terms of
CFSE dilution by flow cytometry. As expected from our pre
vious result (Fig. 5 B), CD8+ T cell proliferation is strongly
diminished by PLC2cKO MDSCs compared with control. In
contrast, PLC2cKO/-cat.CA MDSCs have significantly
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Figure 6. Down-regulation of -catenin
regulates MDSC accumulation and tumor
growth. (A) Western blot analysis displaying
expression levels of PLC2, -catenin, p-PKC and
p-GSK3 in MDSCs isolated from tumor-bearing
WT and PLC2/ mice. -actin was used as
loading control. One representative blot out of 3
independent experiments is shown. (B) Western
blot analysis displaying expression levels of
PLC2 and -catenin in PLC2/ MDSCs stimulated with PDBu or saline for 18 h. -actin was
used as loading control. One representative blot
out of two independent experiments is shown.
(C) 105 LLC cells were s.c. injected in -cat.cKO or
control mice (CTR) and tumor growth followed
for 14 d. BM, spleen and tumors were then
analyzed by FACS using anti–Gr-1 and CD11b
staining to measure the percentage of MDSCs.
Mean ± SD (n = 8) are shown. One representative
out of 3 independent experiments is shown.
*, P < 0.05, **, P < 0.01, ***, P < 0.001. (D) WT mice
s.c. inoculated with LLC cells were adoptively
transferred on days 3 and 6 with 3 × 106 CTR- or
-cat.cKO-MDSCs isolated from LLC tumor–bearing
mice. Saline injection was used as control. Tumor
growth was followed for 14 d. The percentage of
MDSCs was determined by FACS in spleen 14 d
after tumor inoculation. Mean ± SD (n = 6) are
shown. Data are reported from one of two similar
independent experiments. **, P < 0.01.
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Figure 7. Increased -catenin expression inhibits MDSC expansion, activity, and tumor growth. (A) 105 LLC cells were s.c. injected in -cat.CA
or control mice (CTR), and tumor growth was followed for 14 d. Bone marrow, spleen, and tumors were then analyzed by FACS using anti–Gr-1 and
CD11b staining to measure the percentage of MDSCs. Mean ± SD (n = 4) are shown. One representative out of two independent experiments is shown.
*, P < 0.05; **, P < 0.01. (B) T cell proliferation assay. MDSCs were isolated from CTR and -cat.CA mice, co-cultured with CFSE-labeled splenocytes from
WT mice (1:5 and 1:1 ratios) and stimulated with anti-CD3 (10 µg/ml) for 3 d. Bar graphs show mean ± SD of three independent experiments. *, P < 0.05.
Representative flow cytometric analysis of gated CD8+ T cell proliferation in the presence of CTR- (dashed line) and .cat.CA-MDSCs (solid line) is also
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less ability to suppress T cell proliferation compared with
PLC2cKO MDSCs (Fig. 7 F). All together these findings
reveal that stabilization of -catenin in PLC2/ MDSCs
modulates MDSC expansion and their suppressive activity.

DISCUSSION
The mechanism behind MDSC differentiation and the signals
that control their commitment and biological function in
tumor-bearing hosts are not well understood. MDSCs have
been detected in bone marrow, secondary lymphoid organs,
and tumor site in many murine tumor models and in patients
with advanced malignancies (Young et al., 1988; Gabitass
et al., 2011; Porembka et al., 2012).The variability in the percentage of MDSCs and their efficiency to suppress antitumor
T cell responses depend on the type and stage of tumor (Youn
et al., 2008; Dolcetti et al., 2010;Younos et al., 2011). Several
studies focused on identifying tumor-derived factors involved
in the accumulation of MDSCs (Bronte et al., 2000; Barreda
et al., 2004; Serafini et al., 2006; Pan et al., 2008; Roland et al.,
2009; Xiang et al., 2009). Fewer studies, however, analyzed
the signaling pathways involved in MDSC expansion in the
tumor host. We now provide new evidence demonstrating
that down-regulation of PLC2 and -catenin signaling promotes MDSC accumulation in the bone marrow and subsequent recruitment to secondary lymphoid organs and tumor
site, where they favor tumor escape from immune control.
We found that PLC2/ MDSCs, with reduced -catenin
levels, are increased in number and strongly suppress CD8+
T cell activity via production of ROS and NO species. This
increase in MDSC number and immune suppressive effects is
likely responsible for the greater s.c growth of LLC and B16
tumor cell lines and for the allogeneic tumor progression

shown. (C) WT mice were lethally irradiated and transplanted with bone marrow cells from PLC2cKO, LysM-Cre (CTR), or PLC2cKO/-cat.CA to generate
chimeric mice. Western blot analyses show the expression of PLC2, -catenin, p-PKC, p-GSK3, and -actin in MDSCs from chimeric mice. 4 wk after
BM transplantation, chimeric mice were inoculated s.c. with 105 LLC cells and tumor growth was followed for 14 d. Percentage of MDSCs in bone marrow,
spleen, and tumor was analyzed by FACS at time of sacrifice. Mean ± SD (n = 10) are shown. Data are reported from one of two similar independent
experiments. **, P < 0.01; ***, P < 0.001. (D and E) 105 LLC cells were s.c. injected in PLC2cKO, CTR, or PLC2cKO/-cat.CA mice. 5 d after tumor challenge,
the tumor was resected and weighed (D). Percentage of MDSCs from bone marrow, spleen, and tumor were then analyzed by FACS staining (Gr-1+CD11b+,
MDSCs) (D). Dissected tumors were stained with anti-CD8 antibody and the percentage of CD8+ T cells was determined by FACS (E). Results represent
mean ± SD (n = 3). One representative out of two independent experiments is shown (D and E). *, P < 0.05; **, P < 0.01. (F) T cell proliferation assay. 5 d
after LLC tumor inoculation, MDSCs were isolated from CTR, PLC2cKO, and PLC2cKO/-cat.CA mice, co-cultured for 3 d with CFSE-labeled splenocytes
from WT mice (1:5 and 1:1 ratios), and stimulated with anti-CD3 (10 µg/ml). Bar graphs show mean ± SD of three independent experiments. *, P < 0.05.
JEM Vol. 210, No. 11
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Reduced PLC2/-catenin in MDSCs occurs during
tumor progression in mice and cancer patients
We then wondered if down-regulation of PLC2–-catenin
pathway is an important regulatory mechanism involved in
the aberrant MDSC expansion and/or activity during tumor
progression. To test the hypothesis that down-regulation of
PLC2–-catenin pathway occurs in WT MDSCs, we compared protein expression levels of phosphorylated-PLC2
(p-PLC2) and -catenin in MDSCs isolated from tumorfree and tumor-bearing WT mice. Strikingly, we found downregulation of p-PLC2 and -catenin levels in MDSCs isolated
from WT tumor-bearing mice compared with tumor-free
controls. Both LLC and B16 tumor cell lines induced a similar phenomenon (Fig. 8 A).
Because various studies implicated MDSCs in the metastatic process (Li et al., 2013; Sawant et al., 2013; Yu et al.,
2013), we wondered whether down-regulation of PLC2/
-catenin signaling in MDSCs would also occur at late stages
of tumor dissemination. To answer this question, we injected
firefly-conjugated B16 melanoma (B16-Fl) cells into the left
ventricle of WT animals, a model widely used to study tumor
dissemination to bone, visceral organs, and lungs in C57BL/6
mice (Arguello et al., 1988; Kang et al., 2003). Animals receiving
saline were used as negative control. Recruitment of tumor
cells to bone was assessed by bioluminescence imaging. Mice
were sacrificed on day 14 when tumor cells were readily detectable in bones, and increased percentage of MDSCs in the
bone marrow and the spleen compared with tumor-free controls was confirmed by FACS. Importantly, we also observed
reduced p-PLC2 and -catenin protein levels in MDSCs
isolated from spleens of animals bearing bone metastases
compared with controls (Fig. 8 B).Thus, the down-regulation
of PLC2–-catenin axis in MDSCs occurs in mice with
primary s.c. tumors as well as during tumor dissemination.
As increased percentage of MDSCs in peripheral blood
correlates with disease progression and stage in many human
cancers, including pancreatic cancer (Porembka et al., 2012),
we isolated MDSCs from PBMCs of pancreatic cancer patients and healthy donors to compare p-PLC2 and -catenin

expression levels. Similarly to mice, we isolated the whole
human MDSC population, characterized by the co-expression
of CD11b and the common myeloid marker CD33 (Greten
et al., 2011; Filipazzi et al., 2012). All samples were collected
before surgical or medical therapy. 5 patients (49–74 yr of
age), 2 with resectable T2A or T3 stages and 3 with unresectable T3 or T4 stages of pancreatic ductal adenocarcinoma
were tested by Western blot. Considering the variability between individuals, we normalized protein levels with total
amount of protein loaded visualized by -actin. We found
significant reduction of p-PLC2 and its downstream effector
p-PKC in MDSCs from pancreatic cancer patients compared
with healthy donors. -catenin and p-GSK3 levels were also
decreased (Fig. 8 C). In conclusion these results demonstrate
that the down-regulation of PLC2–-catenin signaling is a
critical step in MDSC expansion in humans and mice.
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of 4T1 breast carcinoma cells observed in PLC2/ mice.
Although a tumor/MDSCs vicious cycle is expected to take
place, in which larger tumors cause greater MDSC expansion
to promote tumor escape from immune control, we found
increased PLC2/ MDSCs numbers at early time points
after tumor inoculation, when differences in tumor size
between WT and KO mice were not present. Although
DC and NK cells from PLC2/ mice also have functional defects and could enhance tumor growth in PLC2/
mice, the MDSCs adoptive transfer studies demonstrate that
PLC2/ MDSCs alone can greatly increase tumor progression in WT recipient mice. This finding indicates that PLC2
controls MDSC development and/or proliferation in response
to the tumor.
Enhanced accumulation of MDSCs is also likely to be responsible for the unexpected bone tumor phenotype recently
observed in PLC2/ animals (Zhang et al., 2011). In the
bone metastasis field, it has been established that bone resorbing
2266

osteoclasts are required to sustain tumor growth in bone. Interestingly, PLC2/ mice display enhanced tumor growth
in bone despite decreased osteoclast numbers, due to impaired
CD8+ T cell activation (Zhang et al., 2011). Thus, expansion
of PLC2/ MDSCs in this tumor model seems to overcome the requirement for active osteoclasts to sustain tumor
growth in bone. Importantly, the down-regulation of PLC2
and -catenin can also occur in MDSCs from WT mice during tumor dissemination to bone, indicating that PLC2/
-catenin pathway modulates MDSC expansion in primary
tumors as well as in a metastatic setting.
Similarly to PLC2-deficient animals, mice with deletion
of -catenin in the myeloid compartment are more susceptible
to tumor growth due to increased MDSC numbers, whereas expression of a constitutively active form of -catenin decreases
MDSC accumulation and tumor growth. Importantly, expression
of -catenin constitutively active in PLC2-deficient MDSCs
is also sufficient to reduce the expansion and the immune
PLC2/-catenin pathway regulates MDSCs in cancer | Capietto et al.
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Figure 8. Reduced p-PLC2 and -cat
enin expression levels are observed in MDSCs during tumor progression in mice and
humans. (A) Western blot analyses show
p-PLC2 and -catenin protein levels in
MDSCs from tumor-free (No Tumor) and LLC or
B16 tumor-bearing C57BL/6 WT mice. -actin
was used as loading control. Mean ± SD of
three tumor-free mice (No Tumor) and three
tumor-bearing mice (Tumor). **, P < 0.01;
***, P < 0.001. (B) 104 B16-Fl cells were i.v. injected in WT mice to allow tumor dissemination
to bone. When bone metastases (Met.) were
established, animals were sacrificed and bone
marrow and spleen were analyzed by FACS
using anti–Gr-1 and -CD11b antibodies to
measure the percentage of MDSCs. Mice
receiving saline i.v. injection were used as
controls (No Tumor). Mean ± SD (n = 4) is
shown. Data are reported from one of two
similar independent experiments. *, P < 0.05.
Western blot analysis of p-PLC2, -catenin
and -actin (loading control) levels in MDSCs
from spleen of mice with bone metastases
(Met.) or tumor-free controls (No Tumor). One
representative Western blot from three different
mouse samples is shown. (C) MDSCs isolated
from healthy donors (HD) or pancreatic cancer patients (Pt) were analyzed for -catenin
and phosphorylation levels of PLC2, PKC,
and GSK3. -actin was used as loading control. Graph shows semiquantitative analysis of
protein levels from Western blots of all samples after normalization to total protein
loaded into the gel (measured by -actin).
Three representative patients out of five are
shown. *, P < 0.05.
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with WT, whereas the rescue of PKC activation by PDBu in
PLC2/ MDSCs increases -catenin protein levels. Nevertheless, we cannot exclude additional PLC2-independent
down-regulation of -catenin in MDSCs, possibly via modulation of Wnt ligands or Wnt inhibitors by the tumor cells.
How does -catenin control MDSC expansion? Elevated
levels of -catenin are often associated with increased cell
proliferation.This is especially true for cancer cells.Therefore, it
was puzzling to observe that MDSC expansion was associated
with reduced -catenin levels. -catenin has been extensively
analyzed in hematopoiesis, at times leading to contradictory
findings. Conditional expression of a stabilized, active form of
-catenin in hematopoietic stem cells (HSC) resulted in hematopoietic failure because of a reduction in cell cycle quiescence,
HSC exhaustion, and blocked differentiation. Consistent with
our hypothesis that -catenin limits MDSC expansion, constitutive activation of -catenin in early hematopoietic precursors
significantly reduces the Gr-1+CD11b+ myeloid cell population
(Scheller et al., 2006).Thus, it is possible that down-regulation
of -catenin, rather than controlling MDSC proliferation,
allows MDSC accumulation by preventing their differentiation
into mature myeloid cells. In support of this hypothesis, we find
that in vitro cultures of hematopoietic progenitor cells from
PLC2-deficient mice give rise to less mature myeloid populations but more Gr-1+ cells than WT cultures. Another plausible
mechanism that could lead to accumulation of MDSCs in
tumor-bearing PLC2- and -catenin–null animals would be
through increased differentiation from myeloid progenitors in
the bone marrow. Several transcription factors involved in
myelopoiesis such as interferon-regulatory factor 8 (IRF-8),
C/EBP-, and PU.1 have been demonstrated to regulate
MDSC development (Scheller et al., 1999; Schroeder et al.,
2003; Kirstetter et al., 2006; Marigo et al., 2010). However
IRF-8, PU.1, and C/EBP- are also involved in monocyte/
macrophage maturation, neutrophil differentiation, and/or
DC development (Tamura et al., 2000; Hamdorf et al., 2011;
Batliner et al., 2012; Pham et al., 2012). Therefore, further
studies are required to determine whether down-regulation
of PLC2–-catenin pathway may affect MDSC differentiation via transcriptional regulation.
In conclusion, our results identify the PLC2–-catenin
pathway as a negative modulator of MDSC accumulation and
activation in response to tumors. This finding is clinically relevant because we confirmed down-regulation of PLC2
and -catenin in human MDSCs isolated from pancreatic
cancer patients. This observation is particularly important, as
-catenin targeting is currently in clinical trials because of the
positive role of -catenin on cell growth in many cancers.
However, based on our finding this approach could be undermined by tumor escape from immune control through expansion of MDSCs.
MATERIALS AND METHODS
Animals and tumor models. Animals were housed in a pathogen-free
animal facility at Washington University. 6–8-wk-old littermate mice were
used in all experiments according to protocols approved by the Institutional
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suppressive activity of PLC2/ MDSCs, allowing greater infiltration of CD8+ T cells at tumor site. Consequently, tumor
growth is reduced in PLC2cKO/-cat.CA mice compared
with PLC2cKO animals.The importance of down-regulation
of PLC2–-catenin axis in MDSC accumulation and activity
is not limited to our KO mouse models but it is a general
mechanism involved in the modulation of WT MDSC responses occurring in the presence of tumor, including in cancer
patients. Our data show that pancreatic cancer patients at advanced stage have reduced p-PLC2 and -catenin levels compared with MDSCs isolated from healthy controls.These results
demonstrate that PLC2 is a negative regulator of MDSC expansion and immune suppressive effects in tumor-bearing hosts
via the -catenin pathway in humans and mice. Several questions arise from this finding.
How is PLC2 signaling regulated in MDSCs? Activation
of PLC2, via phosphorylation of its tyrosine residues, is often
observed in hematopoietic cells, including myeloid cells, as
well as in cancer cells downstream of ITAM-containing immune receptors, growth factor receptors, and G protein coupled receptors. Considering that the tumor microenvironment
is enriched with tumor-derived factors that can potentially
signal via PLC2, it was very surprising to observe reduction
of PLC2 phosphorylation in MDSCs from tumor-bearing
mice and cancer patients compared with healthy controls. In
myeloid cells PLC2 activation downstream of ITAM containing receptors can be counterbalanced by negative regulatory signals emanated by receptors containing ITIM domains.
A recent study indicated that the ITIM-containing paired
immunoglobulin-like receptor (PIR) B is highly expressed in
MDSCs (Ma et al., 2011). Deletion of PIR-B switches the
MDSC phenotype from immune-suppressive to proinflammatory, thus leading to reduced tumor growth.Therefore, one
possible mechanism for down modulation of PLC2 activation in WT MDSCs would be through suppression of ITAM
signaling by PIR-B. Because -catenin activation has also
been reported to occur downstream of ITAM receptors
(Otero et al., 2009), reduced -catenin levels in MDSCs isolated from tumor-bearing mice or cancer patients could also
be caused by suppression of ITAM signaling by PIR-B.
How does PLC2 modulate -catenin? Regardless of
which ITAM-containing receptor may activate PLC2 and
-catenin, we propose that these molecules lie on the same
pathway.This assumption is supported by the observation that
-catenin levels are reduced in PLC2/ MDSCs and that
expression of constitutively active -catenin in PLC2/
marrow cells limits MDSC expansion and immune suppressive effects and reduces tumor growth. Although PLC2 has
never been shown to directly modulate -catenin levels, activation of PKC can induce -catenin stabilization in T cells
(Lovatt and Bijlmakers, 2010). It is likely that PKC, a downstream effector of PLC2, phosphorylates and thus inactivates
GSK3, a kinase that targets -catenin for ubiquitination
and subsequent proteasomal degradation. In support of this
hypothesis, we observed impaired PKC phosphorylation and
reduced p-GSK3 levels in PLC2/ MDSCs compared
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Bone marrow transplantation. 4-wk-old female C57BL/6 mice were
lethally irradiated using a 137Cs source with 1,000 rads to generate recipient
mice. Bone marrow was harvested from 6-wk-old female PLC2cKO,
PLC2cKO/-cat.CA, or LysM-Cre control mice. Cells were then suspended
in PBS and 106 cells/200 µl were injected into the lateral tail vein of recipient
mice. 4 wk after bone marrow transplantation, these mice were inoculated
with tumor cells as described above.
Flow cytometric analysis. Immediately upon sacrifice, single-cell suspensions were prepared from bone marrow, spleen, and tumor. In brief, bone
marrow cells were harvested from tibias and femurs by centrifugation,
whereas spleens and tumors were mechanically dissociated and individual cell
suspensions obtained through 70-µm cell strainer. Red blood cells were then
removed with lysis buffer and cells counted. Cell suspensions were then
washed once and stained in PBS with 0.5% FBS with the following anti–mouse
antibodies: allophycocyanin (APC)-conjugated anti–Gr-1 or -Ly6C, FITCconjugated anti-F4/80 (eBioscience); and phycoerythrin (PE)-conjugated
antibodies to CD11b or CD11c, FITC-conjugated anti-Ly6G, -CD11c, -CD86
(B7.2), or -CD45.1, APC-conjugated anti-CD8 (BD). The respective
2268

isotype-matched conjugated controls were purchased from eBioscience and
BD, respectively. Cell surface staining on isolated cells from human PBMCs
were performed using monoclonal (PerCP-Cy5.5)-conjugated anti–human
CD33 antibody (BioLegend) and (PE)-conjugated anti–human CD11b antibody (BD). Corresponding isotope controls yielded no significant staining.
Acquisition was performed on a FACSCalibur and the dedicated software
CellQuest (BD). Data were analyzed with FlowJo 7.5.5 software (Tree Star).
MDSC isolation. In vivo experiments were assessed using freshly isolated
MDSCs from spleens of tumor-bearing mice. Cells were purified by immuno
magnetic separation using biotinylated anti–Gr-1 antibody and streptavidin-conjugated MicroBeads with MiniMACS columns according to the
manufacturer’s protocol (Miltenyi Biotec). In vitro functional and mechanistic assays were done either with whole MDSC population or with PMNand MO-MDSC subsets. Cells were isolated from spleens of tumor-bearing
mice using the Myeloid-Derived Suppressor Cell Isolation kit from Miltenyi
Biotec. Cell purity was checked by flow cytometric analysis using antiCD11b and Gr-1 antibodies (>95%), and viability was checked by Trypan
blue dye exclusion.
Human PBMCs were obtained from D.C. Linehan’s laboratory (Washington University, St Louis, MO) as previously described (Porembka et al.,
2012). In brief, informed consent was prospectively obtained from all
patients before obtaining human blood according to the institutionally
approved Human Studies Committee Protocol. Peripheral blood samples
were collected in vacuum tubes containing EDTA (BD). PBMCs were isolated by Ficoll-density centrifugation and frozen in DMSO with 10% FBS.
Cells were then thawed, washed, and processed for cell isolation using CD33
and CD11b MicroBeads with MiniMACS columns according to the manufacturer’s protocol (Miltenyi Biotec). Purity was confirmed by flow cytometric
(>95%) and Western blot analyses, which were immediately performed.
Real-time PCR. MDSCs from spleens were isolated 14 d after tumor challenge
as previously described. Total RNA was extracted with TRIzol (Invitrogen) and
quantified on ND-1000 spectrophotometer (NanoDrop Technologies). The
cDNA was synthesized with 1 µg RNA using RNA to cDNA EcoDry Premix
(oligo dT) RT-PCR kit from Takara. The amount of Bcl-2, Bcl-xl, or Bax was
determined using Power SYBR Green mix on 7300 Real-Time PCR System
(Applied Biosystems). Cyclophilin mRNA was used as internal control. Specific
primers were as follows: Bcl-2, 5-TGAGTACCTGAACCGGCATCT-3 and
5-GCATCCCAGCCTCCGTTAT-3; Bcl-xl, 5-ACAGAGCAGACCCAGTAAGT-3 and 5-ACCGCAGTTCAAACTCAT-3; Bax, 5-ACAGATCATGAAGACAGGGG-3 and 5-CAAAGTAGAAGAGGGCAACC-3;
cyclophilin, 5-AGCATACAGGTCCTGGCATC-3 and 5-TTCACCTTCCAAAAGACCAC-3. Relative quantification of transcription was calculated as
the power of the difference between amplification of the target gene and amplification of cyclophilin (i.e., 2[Ct target gene  Ct cyclophilin], where Ct represents
threshold cycle).
Generation of cells from bone marrow progenitors. Hematopoietic
progenitor cells (HPCs) were isolated from WT and PLC2/ bone marrow using the Lineage Cell Depletion kit (Miltenyi Biotec). 5 × 105 HPCs
were cultured in 24-well plates containing 2 ml of RPMI 1640 supplemented
with 10% FBS, 20 ng/ml GM-CSF, 10 ng/ml IL-4, and 20% vol/vol tumor
conditioned medium (TCM; Youn et al., 2008). The TCM was generated
from primary EL-4 tumor cells injected into WT C57BL/6 for 2 wk, collected as single-cell suspension with collagenase and cultured for 2 d in
RPMI supplemented with 10% FBS. TCM were frozen at 80°C until further use. After 5 d of HPC cultures, percentages of CD11c+, CD11c+/B7.2+,
F4/80+, and Gr-1+ cells in total WT and PLC2/ cell cultures were analyzed by flow cytometry.
T cell suppression assay. Freshly isolated splenocytes (5 × 106 cells/ml)
from OT-I TCR transgenic mice were depleted of red cells and labeled with
CFSE (1 µM; Molecular Probe, Carlsbad, CA) for 10 min at 37°C and washed
with fresh culture media, according to the manufacturer’s instructions. OT-1
PLC2/-catenin pathway regulates MDSCs in cancer | Capietto et al.
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Animal Care and Use Committee. PLC2/ mice were on a C57BL/6
background and have been previously described (Wang et al., 2000). WT
and PLC2/ littermates were used throughout the study. LysM-Cre/
-cateninflox/flox (conditional KO, -cat.cKO) and LysM-Cre/-cateninfloxEx3/
floxEx3 (constitutively active, -cat.CA) mice on C57BL/6 background were
provided by F. Long (Washington University, St. Louis, MO) and have been
previously described (Clausen et al., 1999; Harada et al., 1999; Brault et al.,
2001). In brief, -cateninflox/flox mice bear two LoxP sites flanking exons
2–6, which lead to a loss-of-function deletion upon Cre-mediated excision.
In -cateninfloxEx3/floxEx3 mice, excision of exon 3 leads to a stabilized, nondegradable form of -catenin. C57BL/6 PLC2flox/flox mice were obtained
from T. Kurosaki (Kansai Medical University, Moriguchi, Japan; Hashimoto
et al., 2000, and the mating strategy to obtain the conditional KO under the
LysM-Cre promoter (PLC2cKO) was performed in our laboratory. LysM-Cre
and floxed littermates were used as controls (CTR). All in vivo figures
are shown as representative experiments. Importantly, significant differences are maintained when all CTR groups are pooled together (Fig. 6 C
and Fig. 7 A).
CD45.1 C57BL/6 WT mice used for the MDSC transfer experiments
were purchased from The Jackson Laboratory. C57BL/6 OT-1 mice were obtained from M. Colonna’s laboratory (Washington University, St Louis, MO).
B16 (C57BL/6 murine melanoma cells), LLC (C57BL/6 murine LLC
cells), and 4T1 (BALB/c murine mammary tumor cells) were cultured at
37°C in complete media (DMEM supplemented with 2 mM l-glutamine,
100 µg/ml streptomycin, 100 IU/ml penicillin, and 1 mM sodium pyruvate)
containing 10% FBS. To establish tumors, B16 (105), LLC (105) or BALB/c
4T1 (5 × 106) tumor cells were suspended in PBS and inoculated s.c. in the
flank of mice. Tumor measurements were performed every 2 or 3 d with a
caliper, and volumes were calculated using the following formula: V = ½
(length [mm] × [width {mm}]2).
For adoptive transfer experiments, appropriate control mice and indicated KO (PLC2/ or -cat.cKO) animals were s.c. injected with 105
LLC. 14 d after tumor xenograft, MDSCs were isolated from the spleen as
described below, and 3 × 106 MDSCs were i.v. injected into WT tumorbearing mice on days 3 and 6 after tumor challenge. WT mice receiving saline injection on days 3 or 6 were used as additional controls.
104 firefly-conjugated B16 melanoma cells (B16-Fl) suspended in 50 µl
of saline solution were injected into the left cardiac ventricle (i.v.) of 6-wk-old
female mice as previously described (Arguello et al., 1988; Kang et al., 2003).
Recruitment of tumor cells to bone was monitored on days 9, 12, and 14
by bioluminescence imaging using an IVIS 100 imaging system (Caliper
Life Sciences). Mice with extrapleural intrathoracic tumors were excluded
from analysis. Bioluminescence photon flux (photons per second) data were
analyzed by region of interest measurements in Living Image 3.2 (Caliper
Life Sciences).
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splenocytes were specifically stimulated with SIINFEKL peptide (10 pM) or
nonspecifically stimulated with anti-CD3 antibody (10 µg/ml). Purified
whole MDSC population or PMN- and MO-MDSC subsets from spleen
were cultured for 3 d in RPMI 1640 (10% FBS) in U-bottom 96-well plates
with 2 × 105 CFSE-labeled splenocytes at different ratio (1:10, 1:5 and 1,1).
Experiments were performed in triplicate.To further analyze the CD8+ T cell
proliferation, cells were stained for CD8 and analyzed for CFSE dilution
using FACSCalibur. The data are expressed as the percentage of proliferation
of stimulated CD8+ CFSE+ T cells.

PKC stimulation. Bone marrow cell suspensions were harvested as pre
viously described and plated in 6-well plates (3 × 106 cells/ml) with RPMI
supplemented with 2 mM l-glutamine, 100 µg/ml streptomycin, 100 IU/ml
penicillin, 1 mM sodium pyruvate, and 10% FBS for 18 h in the presence or
not of PDBu (10 ng/ml). MDSCs were then isolated as previously described
and prepared for Western blot analyses as described below.
Western blotting. MDSCs were isolated as previously described and immediately lysed with RIPA buffer in the presence of protease and phosphatase inhibitors. An equal amount of total protein lysates were subjected to
8% SDS-PAGE gel and transferred to PVDF membranes. Membranes
were blocked in 5% BSA in PBS/Tween-20 for 1 h, and then probed with
appropriate specific primary antibodies overnight at 4°C. Membranes were
washed and incubated for 2 h at room temperature with secondary antibodyconjugated with peroxidase. Results were visualized by chemiluminescence
detection using a SuperSignal West Dura Extended Duration Substrate
(Thermo Fisher Scientific). Antibodies against p-PLC2 (Tyr1217), total
-catenin, p-PKC (pan; II Ser660), and p-GSK3 (Ser9) were obtained
from Cell Signaling Technology. Equal loading was assessed using anti–-actin
antibody (Sigma-Aldrich). Semi-quantifications of protein were determined
using GeneTools software (Syngene).
Statistical analysis. Experiments were done in triplicate and analyzed using
Student’s t test. In calculating two-tailed significance levels for equality of
means, equal variances were assumed for the two populations. Results were
considered significant at P < 0.05.
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